This phase III trial is assessing the safety and effectiveness of neoadjuvant chemotherapy, with docetaxel and anthracycline, in patients with advanced breast cancer.
This trial is treating patients with breast cancer.
This is a systemic therapy trial.
You may be able to join this trial if:
- Your cancer has not spread to other parts of the body.
Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.
Clinical Summary Read More
Use the hyperlinks, where available to access additional clinical trial information.
Neoadjuvant chemotherapy with docetaxel and anthracycline based chemotherapy in patients with advanced breast cancer: Evaluation of biological, clinical and imaging markers of tumour response: A pilot study.
Other Non-Commercial Sponsor
Patients will be given either docetaxcel or anthracycline based chemotherapy prior to surgery. The tumour will be measured both before and after after the chemotherapy. All the measurements including radiological and laboratory from the tumour tissue are then assessed. Trial runs for 24 weeks.
Recruiting Hospitals Read More
Not Recruiting Hospitals Read More